Predictive Significance of Vascular Endothelial Growth Factor receptor VEGF-2 in triple-negative breast cancer patients

The identification of informative biomarkers that are able to predict prognosis and treatment response may be particularly important in triple negative breast cancer.

The aim of the study was to investigate the relationship between vascular endothelial growth factor receptor VEGFR-2 expression and KDR gene polymorphisms with the efficacy of neoadjuvant chemotherapy (NAC) in patients with triple negative breast cancer.

Methods. The study included 70 patients with triple negative operable breast cancer (T1–3N0–3M0), who had received 2–4 cycles of FAC and CAX regimens. The pathologic complete response (pCR) to treatment was determined by RECIST. VEGFR-2 expression level was evaluated using immunohistochemistry. Genotypes for KDR (rs2071559, rs2305948) were detected by a Real-time PCR.

Results. The pCR rate was significantly associated with young age at diagnosis (≤50 years) (p=0.0044), a high level of Ki67 expression (≥20) (p=0.0322) and with CAX regimen (p=0.0246). Additionally, all patients with pCR had the lack of VEGFR-2 expression in tumor tissue after surgery (p=0.0000). The presence of the VEGFR-2 expression (negative or positive) in tumor tissue before NAC was associated with KDR rs2071559 (r=−0.297; p=0.0273). A significant correlation between the KDR rs2071559 and VEGFR-2 expression level (less than 70, 70% or more) in the tumor tissue before NAC was found (r=−0.314; p=0.0297). Multivariate logistic regression analysis showed that the young age of the patients (≤50 years), the lack of VEGFR-2 expression after surgery and CAX regimen were significant predictors of NAC.

Conclusion. The VEGFR-2 expression level in tumor tissue and KDR gene polymorphism can be considered as new additional molecular predictive markers of pathologic complete response to NAC in triple negative breast cancer patients.

1. Brouckaert O., Wildiers H., Floris G., Neven P. Update on triplenegative breast cancer: prognosis and management strategies. Int J Womens Health. 2012; 4: 511–20. doi: 10.2147/IJWH.S18541.

2. Penault-Llorca F., Viale G. Pathological and molecular diagnosis of triple- negative breast cancer: a clinical perspective. Ann Oncol. 2012. Suppl. 6: vi19–22.

3. Perou C.M. Molecular stratification of triple-negative breast cancers. Oncologist. 2011. 16. Suppl 1: 61–70. doi:10.1634/theoncologist.2011- S1-61.

4. Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw. 2009 Dec; 20 (4): 158–63. doi: 10.1684/ecn.2009.0170.

5. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005 Feb 10; 23 (5): 1011–27.

6. Chanana P., Pandey A.K., Yadav B.S., Kaur J., Singla S., Dimri K., Trehan R., Krishan P. Significance of serum vascular endothelial growth factor and cancer antigen 15.3 in patients with triple negative breast cancer. Journal of Radiotherapy in Practice 2014. 13: 60–67. doi: 10.1017/S146039691200057X.

7. Linderholm B.K., Hellborg H., Johansson U., Elmberger G., Skoog L., Lehtiö J., Lewensohn R. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol. 2009 Oct;20 (10): 1639–46. doi: 10.1093/annonc/mdp062.

8. Taha F.M., Zeeneldin A.A., Helal A.M., Gaber A.A., Sallam Y.A., Ramadan H., Moneer M.M. Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancer. Clin Biochem. 2009 Sep; 42 (13–14): 1420–6. doi: 10.1016/j.clinbiochem.2009.06.022.

9. El-Arab L.R., Swellam M., El Mahdy M.M. Metronomic chemotherapy in metastatic breast cancer: impact on VEGF. J Egypt Natl Canc Inst. 2012 Mar; 24 (1): 15–22. doi: 10.1016/j.jnci.2011.12.002.

10. Jansson S., Bendahl P.O., Grabau D.A., Falck A.K., Fernö M., Aaltonen K., Rydén L. The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer. PLoS One. 2014 Jul 15; 9 (7): e102176. doi: 10.1371/journal.pone.0102176.

11. Yan J.D., Liu Y., Zhang Z.Y., Liu G.Y., Xu J.H., Liu L.Y., Hu Y.M. Expression and prognostic significance of VEGFR-2 in breast cancer. Pathol Res Pract. 2015 Jul; 211 (7): 539–43. doi: 10.1016/j.prp.2015.04.003.

12. Guide immunohistochemical diagnosis of human tumors / Ed. by S.V. Petrov, N.T. Raykhlin. Kazan’; 2004, 451 p. [in Russian]

13. Rydén L., Jirström K., Haglund M., Stål O., Fernö M. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Res Treat. 2010 Apr; 120 (2): 491–8. doi: 10.1007/s10549-010-0758-6.

14. Fertig E.J., Lee E., Pandey N.B., Popel A.S. Analysis of gene expression of secreted factors associated with breast cancer metastases in breast cancer subtypes. Sci Rep. 2015 Jul 15; 5: 12133. doi: 10.1038/srep12133.

15. Kallergi G., Markomanolaki H., Giannoukaraki V., Papadaki M.A., Strati A., Lianidou E.S., Georgoulias V., Mavroudis D., Agelaki S. Hypoxiainducible factor- 1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Res. 2009; 11 (6): R84. doi: 10.1186/bcr2452.

16. Pizon M., Zimon D.S., Pachmann U., Pachmann K. Insulin-like growth factor receptor I (IGF-IR) and vascular endothelial growth factor receptor 2 (VEGFR-2) are expressed on the circulating epithelial tumor cells of breast cancer patients. PLoS One. 2013; 8 (2): e56836. doi: 10.1371/journal.pone.0056836.

17. Slonimskaya E.M., Tarabanovskaya N.A., Doroshenko A.V., Garbukov E.Yu., Kokorina Yu.L. Xeloda in neoadjuvant treatment for operable breast cancer. Sibirskiy onkologicheskiy zhurnal. 2009; 1: 14–18 [in Russian].

18. Babyshkina N., Malinovskaya E., Patalyak S., Bragina O., Tarabanovskaya N., Doroshenko A., Slonimskaya E., Perelmuter V., Cherdyntseva N. Neoadjuvant chemotherapy for different molecular breast cancer subtypes: a retrospective study in Russian population. Med Oncol. 2014 Sep; 31 (9): 165. doi: 10.1007/s12032-014- 0165-7.

19. Jinno H., Sakata M., Hayashida T., Takahashi M., Mukai M., Ikeda T., Kitagawa Y. A phase II trial of capecitabine and docetaxel followed by 5- FU/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with II/III stage breast cancer. Ann Oncol. 2010 Jun; 21 (6): 1262–6. doi: 10.1093/annonc/mdp428.

20. Natoli C., Cianchetti E., Tinari N., Angelucci D., Grassadonia A., Zilli M., Ficorella C., Ricevuto E., Grossi S., De Tursi M., Carella C., Rispoli A.I., Iacobelli S. A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. Ann Oncol. 2007 Jun; 18 (6): 1015–20.

21. von Minckwitz G., Rezai M., Fasching P.A., Huober J., Tesch H., Bauerfeind I., Hilfrich J., Eidtmann H., Gerber B., Hanusch C., Blohmer J.U., Costa S.D., Jackisch C., Paepke S., Schneeweiss A., Kümmel S., Denkert C., Mehta K., Loibl S., Untch M. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline- taxane-based chemotherapy for primary breast cancer (GBG 40-GeparQuattro). Ann Oncol. 2014 Jan;25 (1): 81–9. doi: 10.1093/annonc/mdt410.

22. Li Q., Jiang Y., Wei W., Yang H., Liu J. Clinical efficacy of including capecitabine in neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2013;8(1):e53403. doi: 10.1371/journal.pone.0053403.

23. Beeghly-Fadiel A., Shu XO., Lu W., Long J., Cai Q., Xiang Y.B., Zheng Y., Zhao Z., Gu K., Gao Y.T., Zheng W. Genetic variation in VEGF family genes and breast cancer risk: a report from the Shanghai Breast Cancer Genetics Study Cancer Epidemiol Biomarkers Prev. 2011 Jan; 20 (1): 33–41. doi: 10.1158/1055-9965.EPI-10- 0793.

24. Försti A., Jin Q., Altieri A., Johansson R., Wagner K., Enquist K., Grzybowska E., Pamula J., Pekala W., Hallmans G., Lenner P., Hemminki K. Polymorphisms in the KDR and POSTN genes: association with breast cancer susceptibility and prognosis. Breast Cancer Res Treat. 2007 Jan; 101 (1): 83–93.

25. Schneider B.P., Radovich M., Sledge G.W., Robarge J.D., Li L., Storniolo A.M., Lemler S., Nguyen A.T., Hancock B.A., Stout M., Skaar T., Flockhart D.A. Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat. 2008 Sep; 111 (1): 157–63.

26. Dorjgochoo T., Zheng Y., Gao Y.T., Ma X., Long J., Bao P., Zhang B., Wen W., Lu W., Zheng W., Shu XO., Beeghly-Fadiel A. No association between genetic variants in angiogenesis and inflammation pathway genes and breast cancer survival among Chinese women. Cancer Epidemiol. 2013 Oct; 37 (5): 619–24. doi: 10.1016/j.canep.2013.06.005.